MENU
October 26, 2021 - 10a pacific, 11a mountain, 12p central, 1p eastern

Advancing Precision Medicine: IVD NGS Solutions and their clinical impact in cancer care

The past decade has been an exciting era in healthcare for patients and providers with the increasingly broad adoption of precision medicine in drug development, clinical trials and approvals. At the forefront of this trend is oncology.  In oncology alone, by 2019, more than 160 biomarkers were approved for targeted therapy selection by the U.S. Food and Drug Administration (FDA). Further, more than 90 percent of pivotal clinical trials currently underway are to evaluate drugs aimed at specific molecular targets for the treatment of cancer. Next-generation sequencing (NGS) has emerged as an ideal solution for companion diagnostics development because it enables testing for multiple biomarkers associated with multiple therapies simultaneously from a single sample.  Shorter turnaround times (TAT) for NGS results are increasingly critical to match patients with appropriate targeted therapies without delaying care, especially for patients with aggressive or late-stage cancers.  Over the past five years, more than 20 pharmaceutical companies have announced companion diagnostics partnerships with leading NGS companies, including Thermo Fisher Scientific.  Oncomine NGS CDx has expanded partnership with over 12 pharmaceutical companies.  Its first generation CDx, Oncomine Dx Target Test, is approved and reimbursed by government and commercial insurers in over 15 countries, including U.S., Europe, Japan, South Korea and Middle East, covering more than 550 million lives globally.  Its new generation CDx, Oncomine Dx Express Test on Genexus system, is currently in development for future regulatory submissions. 

Join us for an in-depth discussion with Jane Li, Director of Pharma Commercialization with Thermo Fisher Scientific, followed by an open panel Q&A with Jane and Matt Beer, Director of Medical Affairs, Thermo Fisher Scientific


Speakers
  • Matt Beer

    Director, North America Medical Affairs, Clinical Sequencing Division, Thermo Fisher Scientific
    BIOGRAPHY
  • Jane Li

    Senior Director, Global Companion Diagnostics Pharma Commercialization, Clinical Sequencing Division, Thermo Fisher Scientific
    BIOGRAPHY

Show Resources
You May Also Like
DEC 07, 2021 3:00 PM EST
DEC 07, 2021 3:00 PM EST
Date: December 7, 2021 Time: 12:30-5:00 p.m. ET #NCATS10...
JAN 25, 2022 1:00 AM PST
JAN 25, 2022 1:00 AM PST
Europe - 10:00 AM Central European Time United Kingdom - 10:00 AM British Summer Time North America - 10:00 AM Central Standard Time Lab Compliance Connect – The world’s leading...
NOV 09, 2022 6:00 AM PST
NOV 09, 2022 6:00 AM PST
Thirteen years ago Labroots launched a new system of learning for a global scientific audience. Now, the 2022 Clinical Diagnostics and Research Virtual Event will again bring together clinic...
APR 19, 2022 6:00 AM PDT
APR 19, 2022 6:00 AM PDT
LabRoots is excited to announce our 10th Annual Genetics Virtual Week held on April 19-21, 2022! Genetics Virtual Week 2022 will offer a multi-day content-rich program combining stellar expe...
SEP 06, 2022 6:00 AM PDT
SEP 06, 2022 6:00 AM PDT
LabRoots is excited to bring academia and industry, research experts, virologists, microbiologists, healthcare professionals, and leading biomedical scientists under one roof at our 8th Annu...
MAR 23, 2022 6:00 AM PDT
MAR 23, 2022 6:00 AM PDT
LabRoots is pleased to announce the 5th Annual 2021 Cannabis Sciences Virtual Event . LabRoots will host the event on March 23, 2022. The Cannabis Sciences planning committee will be plannin...
Help

Loading Comments...
Show Resources